Press release
Initial Hearing Scheduled in Federal Actos Bladder Cancer Litigation
Nadrich & Cohen, LLP reports that the federal judge presiding over the consolidated Actos bladder cancer cases has scheduled the first hearing in the pending litigation.Los Angeles, CA, February 14, 2012 – Judge Rebecca Doherty issued an order on Monday announcing that she would be appointing lead counsel for the consolidated Actos lawsuits following a March 22nd status conference set to take place in Lafayette, LA. Judge Doherty was assigned to oversee the proceedings after the U.S. Judicial Panel on Multidistrict Litigation voted to centralize all federal Actos lawsuits in the U.S. District Court for the Western District of Louisiana in December 2011.
The plaintiffs in the lawsuits allege that Actos (pioglitazone) caused them to develop serious side effects, including bladder cancer. The litigants also claim that the drug’s manufacturer, Takeda Pharmaceuticals, knew of the potential bladder cancer risk but failed to adequately warn consumers of the possible dangers.
The lawsuits against Takeda and co-defendant Eli Lilly began mounting following a June 2011 safety communication issued by the U.S. Food and Drug Administration. In their announcement, the FDA warned that patients who used Actos for a year or more were at an elevated risk of developing bladder cancer. Following the announcement, sales of Actos have declined slightly but the drug remains a popular treatment alternative for adult patients with Type 2 diabetes.
Reportedly, the number of lawsuits filed against Takeda nationwide total less than 200 but that number is expected to grow. A December 2011 Bloomberg article suggested that Takeda could face 10,000 or more lawsuits in connection with patients who suffered Actos side effects.
Patients who were diagnosed with bladder cancer after taking Actos may be eligible to file a claim for compensation. These individuals are encouraged to seek the aid of an experienced personal injury lawyer to discuss their legal rights.
Nadrich & Cohen LLP is offering confidential, no-cost consultations to patients who believe they developed bladder cancer after using Actos. Help is available by calling the firm’s injury hotline at 1-800-718-4658 or by completing an online contact form at www.sideeffectactos.com.
Nadrich & Cohen LLP is a national law firm with offices in Los Angeles, Sacramento, San Diego and other cities throughout California specializing in handling mass tort actions and representing individuals in cases involving pharmaceutical companies and medical device manufacturers. The firm is committed to achieving the best outcome possible in every case and has recovered over $200 million in settlements on behalf of its clients.
In addition to handling Actos side effects claims, the firm is also actively investigating cases involving Yaz, DePuy ASR hips, Zoloft, Fosamax, Paxil, Wright Conserve Hips, Stevens-Johnson Syndrome, Benzene, Reflex Sympathy Dystrophy, Fen Phen and Asbestos exposure. For more information, visit www.personalinjurylawcal.com.
Jennifer Poole
National Client Intake Coordinator
Nadrich & Cohen LLP
12100 Wilshire Blvd.
Suite 1250
Los Angeles, CA 90025
800-718-4658
info@personalinjurylawcal.com
www.personalinjurylawcal.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Initial Hearing Scheduled in Federal Actos Bladder Cancer Litigation here
News-ID: 210968 • Views: …
More Releases from Nadrich & Cohen LLP
Yaz Lawsuit Settlements Reach $142 Million
Nadrich & Cohen, LLP reports that Bayer is continuing to offer settlements to plaintiffs involved in federal Yaz side effects litigation.
Los Angeles, CA, April 27, 2012 – Nadrich & Cohen, LLP reports that German drug-maker Bayer AG has settled approximately 651 Yaz side effects lawsuits totaling $142 million. Earlier this month, it was reported that the drug-maker had reached settlements in approximately 500 cases filed by women who claimed…
Yaz, Yasmin to Get New Labels as FDA Warns of Blood Clot Risk
Nadrich & Cohen, LLP reports that Yaz and similar birth control pills are to receive updated warning labels advising patients of the risk for developing serious blood clots.
Los Angeles, CA, April 10, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has ordered Bayer to produce new warning labels for several of its oral contraceptives, including Yaz, Yasmin and Beyaz.…
FDA Schedules Advisory Panel Meeting to Discuss Metal Hip Safety
Nadrich & Cohen, LLP reports that the FDA has scheduled an advisory panel to discuss the safety of metal hip implants.
Los Angeles, CA, March 29, 2012 – National law firm Nadrich & Cohen, LLP has learned that the U.S. Food and Drug Administration has a scheduled an advisory panel meeting to discuss the safety of metal hip implants and all-metal hip resurfacing systems.
The two-day panel, which is expected…
Pradaxa Side Effects Lawsuits Filed in Federal Court
Nadrich & Cohen, LLP reports that three Pradaxa side effects lawsuits have been filed in federal courts across the country.
Los Angeles, CA, March 7, 2012 – National law firm Nadrich & Cohen, LLP has learned that three Pradaxa side effects lawsuits have been filed against Boehringer Ingelheim, the drug’s manufacturer. The cases were filed in federal district courts located in Tennessee, Kentucky and Louisiana and it’s believed they are the…
More Releases for Actos
Federal Panel Votes to Consolidate Actos Bladder Cancer Lawsuits
Nadrich & Cohen LLP reports that a federal judicial panel has voted to consolidate pending Actos bladder cancer claims into a multidistrict litigation for pretrial proceedings.
Los Angeles, CA, January 5, 2012 – Plaintiffs in the Actos bladder cancer litigation have successfully moved to have the federal lawsuits consolidated into a multidistrict litigation for pretrial proceedings. The cases will be transferred to the Western District Court of Louisiana, with the…
More Actos Bladder Cancer Lawsuits Filed in Los Angeles
Nadrich & Cohen LLP reports that new lawsuits have been filed in Los Angeles against the maker of Actos by two patients who allege the drug caused bladder cancer.
Los Angeles, CA, December 30, 2011 – As Takeda Pharmaceuticals continues to battle litigation over its Type 2 diabetes drug Actos, three additional lawsuits were filed in a Los Angeles court. The newest claims join the thousands of other Actos lawsuits that…
Takeda Pharmaceuticals, Eli Lilly Face Actos Class Action Lawsuit in Canada
Los Angeles, CA, December 22, 2011 – A class action lawsuit was filed in an Ontario Superior Court against Japanese drug-maker Takeda Pharmaceuticals, alleging that the company knew its popular Type 2 diabetes drug Actos causes bladder cancer. The class action suit also names Eli Lilly as a defendant.
According to court records, the lead plaintiff in the action is a Toronto woman who began taking Actos in 2002. The…
Despite Bladder Cancer Lawsuits, Generic Actos May Hit Market Next Year
Takeda Pharmaceuticals, the manufacturer of Type 2 diabetes drug Actos, may face stiff competition from generic competitors when the drug’s patent expires in August 2012. The Japanese drug-maker also faces trouble on another front in the form of thousands of lawsuits filed by Actos users who allege the drug caused them to develop bladder cancer.
Takeda has previously settled lawsuits from a number of drug manufacturers which would allow the…
Nadrich & Cohen Now Reviewing Actos Bladder Cancer Claims
Los Angeles, CA, December 12, 2011 – Nadrich & Cohen LLP, a prominent national law firm, is now reviewing claims from Actos users in all 50 states who developed bladder cancer after taking the drug. In an effort to connect with even more Actos users across the country, the firm has established an online resource center at www.SideEffectActos.com.
Actos was approved by the U.S. Food and Drug Administration to treat adults…
FDA Delays Actos Combo Drug Review as Actos Bladder Cancer Lawsuits Continue to …
Los Angeles, CA, December 9, 2011 – As Actos bladder cancer lawsuits continue to mount, the Food and Drug Administration has opted to delay its review of a new Type 2 diabetes drug that combines Actos with algoliptin. The FDA’s decision represents another blow to Japanese drug-maker Takeda Pharmaceuticals, who may face as many 10,000 lawsuits from Actos users who claim they developed bladder cancer after taking the drug.
The…
